Loading
A phase 2 trial of Farletuzumab-exatecan, Bevacizumab, Carboplatin in ovarian cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT07714668 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 171 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-04-30. Interventions recorded: SYS6041, bevacizumab, SYS6041, carboplatin, bevacizumab, paclitaxel, carboplatin, bevacizumab, SYS6041, enlonstobart, bevacizumab. Conditions listed: Ovarian Cancer, Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares CSPC Pharmaceutical Group, Carboplatin.
Shares Farletuzumab-exatecan, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/